January 24, 2025 12:03 PM EST
Pharma
Manufacturing

Take­da dis­con­tin­ues US sup­ply of gout drug Uloric over gener­ic com­pe­ti­tion 

Anna Brown

News Reporter

Take­da has end­ed the man­u­fac­tur­ing and sup­ply of its gout drug Uloric in the US mar­ket as more pa­tients turn to gener­ic ver­sions, the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

The cru­cial obe­si­ty da­ta to watch for this year

Up­com­ing PDU­FA dates may be en­snared by Trump's pause at HHS, an­a­lyst says

With Sam Alt­man’s help, Retro Bio­sciences eyes $1B to ex­tend lifes­pan by 10 years

No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al

Mer­ck and Ei­sai re­veal late-stage fail for Keytru­da and Lenvi­ma in gas­troe­sophageal can­cer

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times